5cancer

619 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
619
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
41
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

5cancer

  1. 1. Nanotechnology in Cancer Treatment
  2. 2. Background and Introduction  Cancer Development of abnormal cells that divide uncontrollably which have the ability to infiltrate and destroy normal body tissue  Chemotherapy Use of anti-cancer (cytotoxic) drugs to destroy cancer cells. Work by disrupting the growth of cancer cells  Nonspecificity  Toxicity  Adverse side effects  Poor solubility
  3. 3.  Cancer Nanotechnology interdisciplinary research, cutting across the disciplines of  Biology  Chemistry  Engineering  Physics  Medicine Nanoparticles  Semiconductor quantum dots (QDs)  Ion oxide nanocrystals  Carbon nanotubes  Polymeric nanoparticles Liposomes Unique Properties  Structural  Optical  Magnetic
  4. 4. • Tumors generally can’t grow beyond 2 mm in size without becoming angiogenic (attracting new capillaries) because difficulty in obtaining oxygen and nutrients.• Tumors produce angiogenic factors to form new capillary structures.• Tumors also need to recruit macromolecules from the blood stream to form a new extracellular matrix.• Permeability-enhancing factors such as VEGF (vascular endothelial growth factor) are secreted to increase the permeability of the tumor blood vessels.
  5. 5. Tissue selectivityTissues with a leaky endothelial wall contribute to asignificant uptake of NP. In liver, spleen and bonemarrow, NP uptake is also due to the macrophagesresiding in the tissues.
  6. 6. • In tumors the uptake depends on the so-called enhanced permeability and retention effect (EPR).
  7. 7. TUMOR-TISSUE TARGETING
  8. 8. Schematic of EPR (enhancedpermeability and retention) effect insolid tumors:1- nanovehicles passively target to vasculatureand extravasate through fenestrated tumorvasculature.2- the extended circulation time (stealthfeatures) allows accumulation in tumor tissue3- lack of lymphatic drainage prevents removalof nanoparticles after extravasationThis passive targeting process facilitates tumortissue binding, followed by drug release for cellkilling.Nanovehicles which fail to bind to tumor cellswill reside in the extracellular (interstitial)space, where they eventually becomedestabilized because of enzymatic andphagocytic attack. This results in extracellulardrug release for eventual diffusion to nearbytumor cells and bystander cell.
  9. 9. In vivo distribution of long-circulating radiolabeled liposomes i.v. injected into C26 tumour-bearing miceLiposomes : DPPC ( a saturated lipid)/ 20%GM1 ganglioside ( a stealth Glycolipid)
  10. 10. Targeting tumours vasculature
  11. 11. Vascular targetsVascular endothelial GFVascular cell adhesion moleculeMatrix metalloproteinasesTumour targetsHuman epidermal receptorTransferrin receptorFolate receptor
  12. 12. Affinity-based targeting of tumors. Ruoslahti E et al. J Cell Biol doi:10.1083/jcb.200910104© 2010 Ruoslahti et al.
  13. 13. Saturation of receptors affects the specificity of targeting. Ruoslahti E et al. J Cell Biol doi:10.1083/jcb.200910104© 2010 Ruoslahti et al.
  14. 14. Treating tumors with cooperative nanoparticles. Ruoslahti E et al. J Cell Biol doi:10.1083/jcb.200910104© 2010 Ruoslahti et al.
  15. 15. Molecular Cancer Imaging (QDs) Tumor Targeting and Imaging Emission wavelengths are size tunable (2 nm-7 nm) 4 High molar extinction coefficients Conjugation with copolymer improves size-tunable optical properties of ZnS-capped CdSe QDs biocompatibility, selectivity and decrease cellular toxicity 5
  16. 16.  Correlated Optical and X-Ray ImagingHigh resolution sensitivity in detection of smalltumors 6x-rays provides detailed anatomical locations Polymer-encapsulated QDs No chemical or enzymatic degradations QDs cleared from the body by slow filtrationor excretion out of the body
  17. 17. ANTICANCER DRUG•Passive diffusion •Poorly vascolarized tumor PHYSIOLOGICAL BARRIERS•EPR non cellular based mechanisms region •Acidic enviroments in tumors DRUG DRUG RESISTANCE •Biochemical alterations cellular based mechanisms •Endocytosis/phagocytosis by the cells •Overcome MDR DISTRIBUTION, CLEARANCE OF •Large volume of DRUG distribution •Toxic side-effects on normal cells Controlled tumoral interstitial drug release
  18. 18. TUMOR-TISSUE TARGETINGConventional Nanoparticles Long-circulating Nanoparticles• Size > 100 nm. • Size < 100 nm, “Stealth”, invisible to• Delivery to RES tissues. macrophages.• Rapid effect (0.5-3 hr). • Hydrophylic surface to reduce opsonization (e.g. PEG)• For RES localized tumors (hepatocarcinoma, hepatic • Prolonged half-life in blood compartment. metastasis, non-small cell lung • Selective extravasation in pathological cancer, small cell lung site. cancer, myeloma, lymphoma). • For tumors located outside the RES regions. • Gradually absorbed by lymphatic system.
  19. 19. TUMOR-CELL TARGETING MDR Reversion A) Free doxorubicin enters into the tumor cells by diffusion but is effluxed by Pgp, resulting in the absence of therapeutic efficacy. B) Doxorubicin-loaded NPs adhere at the tumor cell membrane where they release their drug content, resulting in microconcentration gradient of doxorubicin at the cell membrane, which could saturate Pgp and reverse MDR Brigger et al., 2002
  20. 20. V di uscita V didel farmaco(Attività Pgp) ingresso farmaco Conc intracellulare farmaco Diff di conc farmaco esterno/interno
  21. 21. Zhang et al., 2008
  22. 22. Caelyx® is a form of doxorubicin| that is enclosed in liposomes.It is sometimes known as pegylated doxorubicin hydrochloride(PLDH). It is used to treat:•Advanced ovarian cancer that has come back after beingtreated with a platinum-based chemotherapy drug.•Women with advanced breast cancer who have an increasedrisk of heart damage from other chemotherapy drugs.• Aids-related Kaposi’s sarcoma .Myocet® , another form of liposomal doxorubicin, is used totreat advanced (metastatic) breast cancer| in combination withanother chemotherapy drug, cyclophosphamide| .
  23. 23. Alexis et al., 2009
  24. 24. Target: enzimi del rilassamento di DNAInibitori delle topoisomerasi Doxorubicina • Induce complesso ternario DNA-farmaco-Topoisomerasi (filamenti di DNA rotti legati in 5’ a una tirosina dell’enzima) • Danneggia il filamento formando radicali liberi-
  25. 25. Target: microtubuliAntimitotici inibizione di assemblaggio stabilizzazione polimeri.Microtubuli: polimeri di tubulina: crescita richiede GTP alleestremita’ e sui monomeri.Idrolisi di GTP a GDP disassembla microtubulo. Per la stabilitàservono MAP

×